Notice: This company has been marked as potentially delisted and may not be actively trading. Ayala Pharmaceuticals (AYLA) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ayala group building 2nd cold storage facility in CebuAugust 27, 2024 | msn.comADXS Ayala Pharmaceuticals, Inc.August 24, 2024 | seekingalpha.comAyala Pharmaceuticals (ADXS) Earnings Dates & ReportsFebruary 13, 2024 | investing.comAyala Pharmaceuticals Stock (OTC:ADXS) Dividends: History, Yield and DatesDecember 21, 2023 | benzinga.comAdvaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete MergerJanuary 19, 2023 | finanznachrichten.deCancer treatment developers Ayala Pharmaceuticals and Advaxis complete mergerJanuary 19, 2023 | bizjournals.comTrading was temporarily halted for "AYLA" at 07:01 PM with a stated reason of "News pending."January 19, 2023 | marketbeat.comAyala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingNovember 17, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsNovember 16, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsNovember 16, 2022 | finance.yahoo.comRecap: Ayala Pharmaceuticals Q3 EarningsNovember 4, 2022 | msn.comAyala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 4, 2022 | finance.yahoo.comAyala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue EstimatesNovember 4, 2022 | finance.yahoo.comAutoZone To Rise Over 9%? Plus Roth Capital Slashes PT On This Stock By 96%October 20, 2022 | markets.businessinsider.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day SessionOctober 19, 2022 | msn.comAyala, Advaxis MergeOctober 19, 2022 | baystreet.caAyala Pharma, Advaxis Announce Merger - Quick FactsOctober 19, 2022 | markets.businessinsider.comCancer treatment developers Ayala Pharmaceuticals and Advaxis to mergeOctober 19, 2022 | bizjournals.comLab Notes: 4 early stage life sciences firms close financing deals; 2 drug candidates get Fast Track approvalSeptember 30, 2022 | bizjournals.comAyala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid TumorsSeptember 29, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid TumorsSeptember 27, 2022 | finance.yahoo.comAyala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 CongressAugust 24, 2022 | finance.yahoo.comPhiladelphia-area life sciences companies with the largest stock, market cap declines in first half of 2022August 2, 2022 | bizjournals.comAyala Pharmaceuticals Stock Nearly Triples on Twitter Post. Is it a Buy?July 27, 2022 | nasdaq.comAyala Pharmaceuticals Stock Nearly Triples on Desmoid Tumor Treatment NewsJuly 26, 2022 | nasdaq.comHC Wainwright Believes Ayala's Initial Cancer Data Is EncouragingJuly 6, 2022 | finance.yahoo.comAyala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage StudyJuly 5, 2022 | finance.yahoo.comAyala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare ConferenceJune 2, 2022 | finance.yahoo.comAyala Pharma To Report Phase II/III Study Of AL102 In Desmoid Tumors Around Mid-2022May 17, 2022 | nasdaq.comAyala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 16, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApril 27, 2022 | finance.yahoo.comAyala Pharmaceuticals GAAP EPS of -$2.80, revenue of $3.5MMarch 30, 2022 | seekingalpha.comMaxim Group Trims Ayala Pharmaceuticals (NASDAQ:AYLA) Target Price to $12.00Maxim Group cut their target price on Ayala Pharmaceuticals from $22.00 to $12.00 in a research note on Wednesday.March 30, 2022 | marketbeat.comAyala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue EstimatesMarch 28, 2022 | msn.comAyala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate UpdateMarch 28, 2022 | finance.yahoo.comAyala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare ConferenceMarch 9, 2022 | finance.yahoo.comAyala Pharmaceuticals (NASDAQ:AYLA) Will Have To Spend Its Cash WiselyMarch 3, 2022 | finance.yahoo.comAyala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid TumorsFebruary 23, 2022 | finance.yahoo.comAyala Pharmaceuticals, Inc. Common Stock (AYLA)January 19, 2022 | nasdaq.comBuy These 2 Small-Cap Stocks to Double Your Investment, Say AnalystsJanuary 17, 2022 | finance.yahoo.comAyala Pharmaceuticals Inc Shares Fall 4.6% Below Previous 52-Week Low - Market MoverJanuary 13, 2022 | nasdaq.comAyala Pharmaceuticals Inc Shares Fall 4.3% Below Previous 52-Week Low - Market MoverJanuary 7, 2022 | nasdaq.comAyala Pharmaceuticals Announces Key Business Objectives for 2022January 4, 2022 | finance.yahoo.comAyala Pharmaceuticals (NASDAQ:AYLA) Raised to Buy at Zacks Investment ResearchZacks Investment Research raised Ayala Pharmaceuticals from a "hold" rating to a "buy" rating and set a $9.75 price target for the company in a research note on Tuesday.December 28, 2021 | marketbeat.comAyala Pharmaceuticals (NASDAQ:AYLA) Downgraded to Hold at Zacks Investment ResearchZacks Investment Research lowered Ayala Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday.December 9, 2021 | marketbeat.comHow Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%November 18, 2021 | finance.yahoo.comAyala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue EstimatesNovember 15, 2021 | finance.yahoo.comAyala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateNovember 15, 2021 | finance.yahoo.comRural America is losing its pharmaciesNovember 12, 2021 | yahoo.comAyala Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 10, 2021 | finance.yahoo.com Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter. Email Address What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. AYLA Media Mentions By Week AYLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AYLA News Sentiment▼0.000.48▲Average Medical News Sentiment AYLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AYLA Articles This Week▼00▲AYLA Articles Average Week Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SAB Biotherapeutics News MiNK Therapeutics News Pluri News Athira Pharma News Curis News Calidi Biotherapeutics News Cyclo Therapeutics News Finch Therapeutics Group News Cognition Therapeutics News Inhibikase Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AYLA) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredThe AI Crash Begins November 30thMost AI stocks are doomed. I’m not an AI hater. AI will absolutely continue to be the most disruptive tech...Brownstone Research | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AYLA Stock Alerts